Tag: pruritus therapeutics market growth

Backed by market attractiveness analysis, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, wider supply chain intelligence, emerging startup coverage, and detailed product-level insights, The Business Research Company’s 2026 market reports are designed to offer research that is more actionable and strategically valuable than ever.

Pruritus Therapeutics Market Growth Potential: How Will Market Size Shift Through 2030?

The pruritus therapeutics market has shown robust expansion in recent years. Its valuation is expected to rise from $12.38 billion in 2025 to $13.08 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.6%. This prior growth can be linked to factors such as the increasing incidence of inflammatory skin conditions, the heightened application of corticosteroids and antihistamines, an uplift in dermatology research investment, the widening reach of hospital and clinic networks, and the prompt adoption of topical treatments.

The pruritus therapeutics market is projected to experience robust expansion over the coming years, forecast to reach a valuation of $16.88 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 6.6%. This anticipated growth can be attributed to several factors, including advancements in genomics and precision medicine, the emergence of new immunosuppressants, the increasing adoption of digital health and remote dermatology solutions, the expanding market for over-the-counter (OTC) pruritus products, and a heightened emphasis on managing chronic skin diseases. Key trends anticipated during this period involve personalized treatment strategies for pruritus, a stronger emphasis on anti-inflammatory therapies, the development and increased use of topical formulations and delivery systems, further expansion of over-the-counter (OTC) pruritus products, and a growing public awareness of chronic skin conditions.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=39693374&type=smp&name=Pruritus%20Therapeutics%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Pruritus Therapeutics Market Growth Drivers: What’s Behind The Acceleration?

An increasing occurrence of dermatological disorders is projected to stimulate the expansion of the pruritus therapeutics market in the future. These conditions encompass ailments affecting the skin, hair, nails, and mucous membranes, ranging from common issues like acne and eczema to more serious ones such as skin cancer and fungal infections. The specific reason for itching frequently dictates which pruritus treatments are employed for skin-related illnesses. Management of this condition involves various approaches, including topical applications, emollients and moisturizers, immunosuppressant drugs, and anti-itch medications. As an illustration, the American Cancer Society, a US-based non-profit organization focused on cancer eradication, reported in January 2024 that skin cancer cases are anticipated to reach 108,270, marking a 3.2% rise from the 104,930 cases documented in 2023. Consequently, the growing prevalence of dermatological disorders is fueling the expansion of the pruritus therapeutics market.

Pruritus Therapeutics Market Segment Analysis Spotlighting Growth Areas

The pruritus therapeutics market covered in this report is segmented –

1) By Product: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressants, Calcineurin Inhibitors, Other Products

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types

4) By End-User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Corticosteroids: Topical Corticosteroids, Systemic Corticosteroids

2) By Antihistamines: First-Generation Antihistamines, Second-Generation Antihistamines

3) By Local Anesthetics: Topical Local Anesthetics

4) By Counterirritants: Menthol-Based Products, Camphor-Based Products

5) By Immunosuppressants: Topical Immunosuppressants, Systemic Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus Ointment, Pimecrolimus Cream

7) By Other Products: Moisturizers And Emollients, Antipruritic Herbal Remedies, Combination Therapies

Pruritus Therapeutics Market Trends: What’s Defining The Industry’s Next Phase?

Leading companies in the pruritus therapeutics market are concentrating on developing innovative biologic treatments, such as monoclonal antibody therapy, to effectively target and relieve the itching linked to conditions like atopic dermatitis and prurigo nodularis. Monoclonal antibody treatment involves using laboratory-produced molecules specifically engineered to target certain proteins in the body, which are typically involved in disease mechanisms. For instance, in June 2024, Maruho Co., Ltd., a Japan-based pharmaceutical company, introduced Mitchga Subcutaneous Injection (30mg vials) in Japan. This product is designed for treating pruritus associated with atopic dermatitis in children (ages 6-13) and prurigo nodularis in adults and adolescents (ages =13) when other treatments have proven ineffective. The product contains nemolizumab, a humanized monoclonal antibody that targets the interleukin-31 (IL-31) receptor. By inhibiting IL-31, the drug aims to alleviate itching and improve the quality of life for patients suffering from these conditions.

Pruritus Therapeutics Market Leading Companies: Who Holds The Strongest Market Presence?

Major companies operating in the pruritus therapeutics market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Galderma Laboratories LP, Cipla Limited, LEO Pharma AS, Cara Therapeutics Inc., GlaxoSmithKline Plc, Novan Inc., Trevi Therapeutics Inc., AbbVie Biopharmaceuticals, Amgen Inc., Allergan plc, Horizon Therapeutics plc, Kyowa Kirin Co. Ltd., Dermira Inc., Pfizer Consumer Healthcare

View The Full Pruritus Therapeutics Market Report:

https://thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Pruritus Therapeutics Market Geographic Landscape: Which Region Leads Industry Growth?

North America was the largest region in the pruritus treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pruritus therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Delivering more actionable and strategically valuable research, The Business Research Company’s 2026 market reports feature market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights.

Pruritus Therapeutics Market Expansion From $13.07 Billion In 2026 To $16.87 Billion In 2030

The market for pruritus therapeutics has experienced robust expansion over recent years. Its value is projected to rise from $12.38 billion in 2025 to $13.08 billion in 2026, reflecting a compound annual growth rate (CAGR) of 5.6%. This growth during the historical period was driven by several key factors, including a higher incidence of inflammatory skin conditions, greater reliance on corticosteroids and antihistamines, increased investment in dermatological research, broader networks of hospitals and clinics, and the early implementation of topical treatment approaches.

The market for pruritus therapeutics is anticipated to experience substantial expansion over the coming years. By 2030, it is projected to reach a value of $16.88 billion, driven by a compound annual growth rate (CAGR) of 6.6%. Several factors are expected to fuel this growth during the forecast period, including progress in genomics and precision medicine, the development of novel immunosuppressants, the expansion of digital health and teledermatology services, a greater availability of over-the-counter pruritus treatments, and an intensified emphasis on managing chronic skin diseases. Key developments shaping the forecast period include more customized approaches to treating pruritus, a stronger emphasis on anti-inflammatory therapies, advancements in topical drug formulations and delivery technologies, a wider selection of over-the-counter products for itch relief, and growing public awareness regarding chronic skin conditions.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11907&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Pruritus Therapeutics Market Development Factors: Which Trends Are Supporting Demand?

An expected increase in the frequency of skin-related conditions is anticipated to drive the advancement of the pruritus treatment market in the coming years. Dermatological disorders involve issues affecting the skin, hair, nails, and mucous membranes, including conditions like acne, eczema, skin cancer, and fungal infections. The choice of pruritus therapies for such illnesses is frequently guided by the root cause of the itching. These treatments encompass topical applications, emollients and moisturizers, immunosuppressive drugs, and medications for itch relief. As an example, in January 2024, the American Cancer Society, a non-profit organization in the US focused on cancer elimination, projected 108,270 new skin cancer diagnoses, marking a 3.2% rise compared to the 104,930 cases noted in 2023. Consequently, the growing prevalence of dermatological disorders is fueling expansion in the pruritus therapeutics market.

Pruritus Therapeutics Market Segmentation Trends And Revenue Drivers

The pruritus therapeutics market covered in this report is segmented –

1) By Product: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressants, Calcineurin Inhibitors, Other Products

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types

4) By End-User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Corticosteroids: Topical Corticosteroids, Systemic Corticosteroids

2) By Antihistamines: First-Generation Antihistamines, Second-Generation Antihistamines

3) By Local Anesthetics: Topical Local Anesthetics

4) By Counterirritants: Menthol-Based Products, Camphor-Based Products

5) By Immunosuppressants: Topical Immunosuppressants, Systemic Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus Ointment, Pimecrolimus Cream

7) By Other Products: Moisturizers And Emollients, Antipruritic Herbal Remedies, Combination Therapies

Pruritus Therapeutics Market Transformation Trends: Which Innovations Are Driving Change?

Key players in the pruritus therapeutics space are placing a strong emphasis on the development of advanced biologic therapies, most notably monoclonal antibody treatments, designed to precisely address and relieve itching linked to conditions like atopic dermatitis and prurigo nodularis. These monoclonal antibody therapies are built around lab-developed molecules that are specifically crafted to home in on certain proteins associated with disease processes in the body. As an example, Maruho Co., Ltd., a pharmaceutical firm based in Japan, introduced Mitchga Subcutaneous Injection, available in 30mg vials, in June 2024 for the Japanese market. This product is intended to manage pruritus resulting from atopic dermatitis in children aged 6 to 13, as well as prurigo nodularis in both adults and adolescents who are 13 years or older, particularly when existing therapeutic options prove insufficient. The formulation includes nemolizumab, which is a humanized monoclonal antibody that targets the interleukin-31 receptor, thereby working to block IL-31. Through this mechanism, the drug aims to diminish itchiness and enhance the overall quality of life for individuals dealing with these challenging skin conditions.

Pruritus Therapeutics Market Industry Leaders: Which Organizations Are Driving Competition?

Major companies operating in the pruritus therapeutics market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Galderma Laboratories LP, Cipla Limited, LEO Pharma AS, Cara Therapeutics Inc., GlaxoSmithKline Plc, Novan Inc., Trevi Therapeutics Inc., AbbVie Biopharmaceuticals, Amgen Inc., Allergan plc, Horizon Therapeutics plc, Kyowa Kirin Co. Ltd., Dermira Inc., Pfizer Consumer Healthcare

Access The Complete Pruritus Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Pruritus Therapeutics Market Geographic Distribution And Regional Opportunities

North America was the largest region in the pruritus treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pruritus therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

What Is The Forecasted Rise In Market Size Of The Pruritus Therapeutics Market During The Forecast Period?

The pruritus therapeutics market has experienced robust expansion in recent years. Its value is projected to rise from $12.38 billion in 2025 to $13.08 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 5.6%. This historical expansion is linked to factors such as an increasing prevalence of inflammatory skin conditions, enhanced utilization of corticosteroids and antihistamines, a surge in dermatology research funding, the widening of hospital and clinic infrastructures, and the early embrace of topical treatments.

The pruritus therapeutics market size is anticipated to expand significantly over the coming years. This market is projected to reach $16.88 billion in 2030, with a compound annual growth rate (CAGR) of 6.6%. The expected growth during this forecast period stems from factors such as advancements in genomics and precision medicine, the introduction of novel immunosuppressants, the rise of digital health and remote dermatology solutions, an increase in over-the-counter (OTC) pruritus products, and a growing emphasis on managing chronic skin diseases. Prominent trends for the forecast period include personalized pruritus treatment strategies, a heightened focus on anti-inflammatory therapies, the development of topical formulations and delivery systems, an expanding range of over-the-counter (OTC) pruritus products, and increasing awareness of chronic skin conditions.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11907&type=smp

Which Strategic Drivers Are Supporting The Pruritus Therapeutics Market Development?

The increasing occurrence of skin conditions is anticipated to drive the expansion of the pruritus therapeutics market in the future. These disorders encompass conditions affecting the skin, hair, nails, and mucous membranes, spanning from common ailments like acne and eczema to more severe issues such as skin cancer and fungal infections. The specific reason for itching frequently dictates the choice of pruritus treatments for various skin-related illnesses. Such conditions are managed with a range of interventions, including topical applications, emollients and moisturizers, immunosuppressant drugs, and anti-itch medications. An example highlighting this trend is seen in January 2024, when the American Cancer Society, a US-based non-profit organization focused on cancer eradication, projected 108,270 reported skin cancer cases, representing a 3.2% rise from the 104,930 cases recorded in 2023. Consequently, the escalating incidence of dermatological disorders is a key factor boosting the growth of the pruritus therapeutics market.

How Is The Pruritus Therapeutics Market Examined Through Segment Analysis?

The pruritus therapeutics market covered in this report is segmented –

1) By Product: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressants, Calcineurin Inhibitors, Other Products

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types

4) By End-User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Corticosteroids: Topical Corticosteroids, Systemic Corticosteroids

2) By Antihistamines: First-Generation Antihistamines, Second-Generation Antihistamines

3) By Local Anesthetics: Topical Local Anesthetics

4) By Counterirritants: Menthol-Based Products, Camphor-Based Products

5) By Immunosuppressants: Topical Immunosuppressants, Systemic Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus Ointment, Pimecrolimus Cream

7) By Other Products: Moisturizers And Emollients, Antipruritic Herbal Remedies, Combination Therapies

Which Trends Are Supporting The Evolution Of The Pruritus Therapeutics Market?

Leading companies within the pruritus therapeutics market are concentrating on the development of innovative biologic treatments, such as monoclonal antibody therapy, to effectively target and alleviate the itching associated with conditions like atopic dermatitis and prurigo nodularis. Monoclonal antibody treatment involves employing laboratory-produced molecules specifically engineered to target certain proteins in the body, which are typically implicated in disease processes. For instance, in June 2024, Maruho Co., Ltd., a pharmaceutical company based in Japan, launched Mitchga Subcutaneous Injection (30mg vials) in Japan for the treatment of pruritus linked to atopic dermatitis in children (ages 6-13) and prurigo nodularis in adults and adolescents (ages ≥13) when other therapies prove ineffective. This product contains nemolizumab, which is a humanized monoclonal antibody that targets the interleukin-31 (IL-31) receptor. By inhibiting IL-31, the drug aims to relieve itching and enhance the quality of life for patients experiencing these conditions.

Which Companies Are Engaged In The Pruritus Therapeutics Market Environment?

Major companies operating in the pruritus therapeutics market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Galderma Laboratories LP, Cipla Limited, LEO Pharma AS, Cara Therapeutics Inc., GlaxoSmithKline Plc, Novan Inc., Trevi Therapeutics Inc., AbbVie Biopharmaceuticals, Amgen Inc., Allergan plc, Horizon Therapeutics plc, Kyowa Kirin Co. Ltd., Dermira Inc., Pfizer Consumer Healthcare

Access The Complete Pruritus Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report

Which Region Accounts For The Highest Share Of The Pruritus Therapeutics Market?

North America was the largest region in the pruritus treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pruritus therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Pruritus Therapeutics Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=11907&type=smp

Browse Through More Reports Similar to the Global Pruritus Therapeutics Market 2026, By The Business Research Company

Pruritus Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report

Pruritus Therapeutic Market Report 2026

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutic-global-market-report

Pertussis Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/pertussis-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Pruritus Therapeutics Market Grow Between 2026 And 2030?

The size of the pruritus therapeutics market has seen significant expansion over recent years. The market is anticipated to expand from $12.38 billion in 2025 to $13.08 billion in 2026, growing at a compound annual growth rate (CAGR) of 5.6%. Factors contributing to its historical growth include the increasing prevalence of inflammatory skin diseases, enhanced application of corticosteroids and antihistamines, a rise in dermatology research funding, the enlargement of hospital and clinic networks, and the prompt embrace of topical treatments.

The pruritus therapeutics market is projected to experience substantial expansion in the coming years. Its value is anticipated to reach $16.88 billion by 2030, expanding at a compound annual growth rate (CAGR) of 6.6%. This anticipated growth during the forecast period stems from factors such as progress in genomics and precision medicine, the introduction of new immunosuppressants, an increase in digital health and remote dermatology offerings, the expansion of OTC pruritus products, and a stronger emphasis on managing chronic skin conditions. Prominent trends for the forecast duration encompass personalized treatment strategies for pruritus, an amplified focus on anti-inflammatory treatments, the development of topical formulations and advanced delivery systems, the proliferation of over-the-counter (OTC) pruritus products, and heightened public understanding of chronic skin ailments.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11907&type=smp

What Factors Are Contributing To The Growth Of The Pruritus Therapeutics Market?

The increasing occurrence of dermatological conditions is anticipated to fuel the expansion of the pruritus therapeutics market in the future. These disorders encompass conditions affecting the skin, hair, nails, and mucous membranes, spanning from issues like acne and eczema to more severe problems such as skin cancer and fungal infections. The specific origin of the itching frequently dictates which pruritus treatments are employed for dermatological ailments. Management for this condition involves various approaches including topical applications, emollients and moisturizers, immunosuppressant drugs, and anti-itching medications. For example, data from January 2024, released by the American Cancer Society, a US-based non-profit organization focused on eradicating cancer, projects 108,270 reported instances of skin cancer, marking a 3.2% rise from the 104,930 cases recorded in 2023. Consequently, the growing frequency of dermatological disorders is propelling the expansion of the pruritus therapeutics market.

How Is The Pruritus Therapeutics Market Categorized Across Its Segment Groups?

The pruritus therapeutics market covered in this report is segmented –

1) By Product: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressants, Calcineurin Inhibitors, Other Products

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types

4) By End-User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Corticosteroids: Topical Corticosteroids, Systemic Corticosteroids

2) By Antihistamines: First-Generation Antihistamines, Second-Generation Antihistamines

3) By Local Anesthetics: Topical Local Anesthetics

4) By Counterirritants: Menthol-Based Products, Camphor-Based Products

5) By Immunosuppressants: Topical Immunosuppressants, Systemic Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus Ointment, Pimecrolimus Cream

7) By Other Products: Moisturizers And Emollients, Antipruritic Herbal Remedies, Combination Therapies

What Market Trends Are Affecting The Pruritus Therapeutics Market?

Leading companies in the pruritus therapeutics market are concentrating on developing innovative biologic therapies, such as monoclonal antibody treatments, to effectively target and alleviate itching associated with conditions like atopic dermatitis and prurigo nodularis. This monoclonal antibody treatment involves the use of laboratory-produced molecules specifically engineered to target particular proteins in the body, which are typically involved in disease processes. For instance, in June 2024, Maruho Co., Ltd., a Japan-based pharmaceutical company, launched Mitchga Subcutaneous Injection (30mg vials) in Japan for addressing pruritus linked to atopic dermatitis in children (ages 6-13) and prurigo nodularis in adults and adolescents (ages =13) when other treatments prove ineffective. The product incorporates nemolizumab, a humanized monoclonal antibody designed to target the interleukin-31 (IL-31) receptor and inhibit IL-31, with the goal of reducing itching and improving the quality of life for patients experiencing these conditions.

Which Firms Are Influencing Competition In The Pruritus Therapeutics Market?

Major companies operating in the pruritus therapeutics market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Galderma Laboratories LP, Cipla Limited, LEO Pharma AS, Cara Therapeutics Inc., GlaxoSmithKline Plc, Novan Inc., Trevi Therapeutics Inc., AbbVie Biopharmaceuticals, Amgen Inc., Allergan plc, Horizon Therapeutics plc, Kyowa Kirin Co. Ltd., Dermira Inc., Pfizer Consumer Healthcare

Get The Full Pruritus Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report

Which Region Leads The Pruritus Therapeutics Market In Overall Market Size?

North America was the largest region in the pruritus treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pruritus therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Pruritus Therapeutics Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report

Browse Through More Reports Similar to the Global Pruritus Therapeutics Market 2026, By The Business Research Company

Pruritus Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report

Pruritus Therapeutic Market Report 2026

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutic-global-market-report

Pertussis Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/pertussis-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Increase Is Anticipated For The Pruritus Therapeutics Market Over The 2026–2030 Period?

The pruritus therapeutics market size has seen substantial growth recently. It is set to expand from $12.38 billion in 2025 to $13.08 billion in 2026, progressing at a compound annual growth rate (CAGR) of 5.6%. This historical development can be ascribed to several factors, including the increasing occurrence of inflammatory skin conditions, the greater application of corticosteroids and antihistamines, an uplift in dermatology research investment, the broadened scope of hospital and clinic infrastructures, and the early integration of topical therapeutic approaches.

The pruritus therapeutics market is projected to experience substantial expansion in the coming years. By 2030, its valuation is anticipated to reach $16.88 billion, demonstrating a compound annual growth rate (CAGR) of 6.6%. This projected increase throughout the forecast period stems from various factors, including progress in genomics and precision medicine, the emergence of new immunosuppressants, the proliferation of digital health and remote dermatology solutions, the rising availability of over-the-counter (OTC) pruritus products, and a heightened emphasis on managing chronic skin diseases. Key developments anticipated during this timeframe encompass individualized pruritus treatment methods, a greater emphasis on anti-inflammatory therapies, the development of topical formulations and advanced delivery systems, the broadening availability of over-the-counter (OTC) pruritus products, and an escalating recognition of chronic skin conditions.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11907&type=smp

What Underlying Factors Are Accelerating The Growth Of The Pruritus Therapeutics Market?

The increasing prevalence of dermatological disorders is anticipated to propel the expansion of the pruritus therapeutics market going forward. These disorders encompass conditions affecting the skin, hair, nails, and mucous membranes, ranging from common issues like acne and eczema to more severe ailments such as skin cancer and fungal infections. The underlying cause of itching typically guides the selection of pruritus treatments for these dermatological illnesses, which may include topical applications, emollients and moisturizers, immunosuppressant medications, and anti-itch medications. For example, in January 2024, the American Cancer Society, a US-based non-profit organization dedicated to eliminating cancer, projected 108,270 reported cases of skin cancer, representing a 3.2% increase from the 104,930 cases documented in 2023. Consequently, the rising incidence of dermatological disorders is a key factor driving the growth of the pruritus therapeutics market.

How Is The Pruritus Therapeutics Market Segmented Across Key Categories?

The pruritus therapeutics market covered in this report is segmented –

1) By Product: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressants, Calcineurin Inhibitors, Other Products

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types

4) By End-User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Corticosteroids: Topical Corticosteroids, Systemic Corticosteroids

2) By Antihistamines: First-Generation Antihistamines, Second-Generation Antihistamines

3) By Local Anesthetics: Topical Local Anesthetics

4) By Counterirritants: Menthol-Based Products, Camphor-Based Products

5) By Immunosuppressants: Topical Immunosuppressants, Systemic Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus Ointment, Pimecrolimus Cream

7) By Other Products: Moisturizers And Emollients, Antipruritic Herbal Remedies, Combination Therapies

Which Upcoming Trends Are Expected To Influence The Pruritus Therapeutics Market?

Leading companies operating in the pruritus therapeutics market are directing their attention towards developing innovative biologic treatments, such as monoclonal antibody therapies, to effectively target and alleviate itching related to conditions including atopic dermatitis and prurigo nodularis. Monoclonal antibody treatment employs laboratory-produced molecules specifically engineered to identify and act upon certain proteins in the body, which are typically involved in disease processes. For instance, in June 2024, Maruho Co., Ltd., a Japan-based pharmaceutical company, launched Mitchga Subcutaneous Injection (30mg vials) in Japan. This product is indicated for the treatment of pruritus linked to atopic dermatitis in children (ages 6-13) and prurigo nodularis in adults and adolescents (ages ≥13) when other treatments have proven ineffective. The product contains nemolizumab, a humanized monoclonal antibody designed to target the interleukin-31 (IL-31) receptor. By inhibiting IL-31, the drug aims to reduce itching and improve the quality of life for patients experiencing these conditions.

Who Are The Dominant Players Shaping The Pruritus Therapeutics Market Landscape?

Major companies operating in the pruritus therapeutics market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Galderma Laboratories LP, Cipla Limited, LEO Pharma AS, Cara Therapeutics Inc., GlaxoSmithKline Plc, Novan Inc., Trevi Therapeutics Inc., AbbVie Biopharmaceuticals, Amgen Inc., Allergan plc, Horizon Therapeutics plc, Kyowa Kirin Co. Ltd., Dermira Inc., Pfizer Consumer Healthcare

Read the full pruritus therapeutics market report here:

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report

Which Region Is Projected To Dominate The Pruritus Therapeutics Market During The Forecast Period?

North America was the largest region in the pruritus treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pruritus therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Pruritus Therapeutics Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11907&type=smp

Browse Through More Reports Similar to the Global Pruritus Therapeutics Market 2026, By The Business Research Company

Pruritus Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report

Pruritus Therapeutic Market Report 2026

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutic-global-market-report

Pertussis Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/pertussis-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the pruritus therapeutics market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Pruritus Therapeutics Market between 2026 and 2030?

The pruritus therapeutics market has experienced significant expansion in recent years. Its size is expected to rise from $12.38 billion in 2025 to $13.08 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.6%. This growth observed historically is attributable to factors like the increasing occurrence of inflammatory skin diseases, greater utilization of corticosteroids and antihistamines, an uplift in dermatology research funding, the expansion of hospital and clinic networks, and the early embrace of topical therapies.

The pruritus therapeutics market size is anticipated to experience robust expansion over the coming years. Projections indicate it will reach $16.88 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.6%. This projected growth is driven by several factors, including developments in genomics and precision medicine, the emergence of novel immunosuppressant drugs, the increase in digital health and remote dermatology solutions, the expansion of otc pruritus products, and a heightened emphasis on managing chronic skin diseases. Key trends anticipated during this period encompass personalized pruritus treatment approaches, a greater focus on anti-inflammatory therapies, the development of topical formulations and delivery systems, the broadening availability of over-the-counter (otc) pruritus products, and a rising awareness of chronic skin conditions.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11907&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Pruritus Therapeutics Market?

The growing occurrence of skin conditions is anticipated to drive the expansion of the pruritus therapeutics market in the future. These disorders encompass conditions affecting the skin, hair, nails, and mucous membranes, varying from common issues like acne and eczema to more severe ones such as skin cancer and fungal infections. The specific origin of itching frequently dictates the selection of pruritus treatments employed for various skin ailments. Treatment approaches for this condition include topical applications, emollients and moisturizers, immunosuppressant drugs, and anti-itch medications. For instance, in January 2024, the American Cancer Society, a US-based non-profit organization dedicated to eliminating cancer, reported an anticipated 108,270 cases of skin cancer, which represents a 3.2% increase from the 104,930 cases reported in 2023. Consequently, the increased frequency of dermatological conditions is propelling the expansion of the pruritus therapeutics market.

How Is The Pruritus Therapeutics Market Organized Into Various Segments?

The pruritus therapeutics market covered in this report is segmented –

1) By Product: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressants, Calcineurin Inhibitors, Other Products

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types

4) By End-User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Corticosteroids: Topical Corticosteroids, Systemic Corticosteroids

2) By Antihistamines: First-Generation Antihistamines, Second-Generation Antihistamines

3) By Local Anesthetics: Topical Local Anesthetics

4) By Counterirritants: Menthol-Based Products, Camphor-Based Products

5) By Immunosuppressants: Topical Immunosuppressants, Systemic Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus Ointment, Pimecrolimus Cream

7) By Other Products: Moisturizers And Emollients, Antipruritic Herbal Remedies, Combination Therapies

Which Trends Are Guiding The Evolution Of The Pruritus Therapeutics Market?

Leading companies in the pruritus therapeutics market are prioritizing the development of advanced biologic therapies, such as monoclonal antibody treatments, to precisely address and reduce itching linked to conditions like atopic dermatitis and prurigo nodularis. Monoclonal antibody treatment employs laboratory-manufactured molecules designed to target specific proteins in the body, which are often implicated in disease processes. Illustratively, in June 2024, Maruho Co., Ltd., a Japan-based pharmaceutical firm, introduced Mitchga Subcutaneous Injection (30mg vials) in Japan. This product is for treating pruritus related to atopic dermatitis in children (ages 6-13) and prurigo nodularis in adults and adolescents (ages =13) when other treatments have not been effective. The product incorporates nemolizumab, a humanized monoclonal antibody that targets the interleukin-31 (IL-31) receptor, and by inhibiting IL-31, the medication seeks to ease itching and improve the quality of life for patients experiencing these conditions.

Who Are The Top-Performing Companies In The Pruritus Therapeutics Market In Recent Years?

Major companies operating in the pruritus therapeutics market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Galderma Laboratories LP, Cipla Limited, LEO Pharma AS, Cara Therapeutics Inc., GlaxoSmithKline Plc, Novan Inc., Trevi Therapeutics Inc., AbbVie Biopharmaceuticals, Amgen Inc., Allergan plc, Horizon Therapeutics plc, Kyowa Kirin Co. Ltd., Dermira Inc., Pfizer Consumer Healthcare

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report

Which Region Currently Holds The Largest Share Of The Pruritus Therapeutics Market?

North America was the largest region in the pruritus treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pruritus therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Pruritus Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11907&type=smp

Browse Through More Reports Similar to the Global Pruritus Therapeutics Market 2026, By The Business Research Company

Pruritus Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report

Pruritus Therapeutic Market Report 2026

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutic-global-market-report

Pertussis Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/pertussis-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the pruritus therapeutics market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Pruritus Therapeutics Market between 2026 and 2030?

The pruritus therapeutics market has experienced significant expansion in recent years. Its size is expected to rise from $12.38 billion in 2025 to $13.08 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.6%. This growth observed historically is attributable to factors like the increasing occurrence of inflammatory skin diseases, greater utilization of corticosteroids and antihistamines, an uplift in dermatology research funding, the expansion of hospital and clinic networks, and the early embrace of topical therapies.

The pruritus therapeutics market size is anticipated to experience robust expansion over the coming years. Projections indicate it will reach $16.88 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.6%. This projected growth is driven by several factors, including developments in genomics and precision medicine, the emergence of novel immunosuppressant drugs, the increase in digital health and remote dermatology solutions, the expansion of otc pruritus products, and a heightened emphasis on managing chronic skin diseases. Key trends anticipated during this period encompass personalized pruritus treatment approaches, a greater focus on anti-inflammatory therapies, the development of topical formulations and delivery systems, the broadening availability of over-the-counter (otc) pruritus products, and a rising awareness of chronic skin conditions.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11907&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Pruritus Therapeutics Market?

The growing occurrence of skin conditions is anticipated to drive the expansion of the pruritus therapeutics market in the future. These disorders encompass conditions affecting the skin, hair, nails, and mucous membranes, varying from common issues like acne and eczema to more severe ones such as skin cancer and fungal infections. The specific origin of itching frequently dictates the selection of pruritus treatments employed for various skin ailments. Treatment approaches for this condition include topical applications, emollients and moisturizers, immunosuppressant drugs, and anti-itch medications. For instance, in January 2024, the American Cancer Society, a US-based non-profit organization dedicated to eliminating cancer, reported an anticipated 108,270 cases of skin cancer, which represents a 3.2% increase from the 104,930 cases reported in 2023. Consequently, the increased frequency of dermatological conditions is propelling the expansion of the pruritus therapeutics market.

How Is The Pruritus Therapeutics Market Organized Into Various Segments?

The pruritus therapeutics market covered in this report is segmented –

1) By Product: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressants, Calcineurin Inhibitors, Other Products

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types

4) By End-User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Corticosteroids: Topical Corticosteroids, Systemic Corticosteroids

2) By Antihistamines: First-Generation Antihistamines, Second-Generation Antihistamines

3) By Local Anesthetics: Topical Local Anesthetics

4) By Counterirritants: Menthol-Based Products, Camphor-Based Products

5) By Immunosuppressants: Topical Immunosuppressants, Systemic Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus Ointment, Pimecrolimus Cream

7) By Other Products: Moisturizers And Emollients, Antipruritic Herbal Remedies, Combination Therapies

Which Trends Are Guiding The Evolution Of The Pruritus Therapeutics Market?

Leading companies in the pruritus therapeutics market are prioritizing the development of advanced biologic therapies, such as monoclonal antibody treatments, to precisely address and reduce itching linked to conditions like atopic dermatitis and prurigo nodularis. Monoclonal antibody treatment employs laboratory-manufactured molecules designed to target specific proteins in the body, which are often implicated in disease processes. Illustratively, in June 2024, Maruho Co., Ltd., a Japan-based pharmaceutical firm, introduced Mitchga Subcutaneous Injection (30mg vials) in Japan. This product is for treating pruritus related to atopic dermatitis in children (ages 6-13) and prurigo nodularis in adults and adolescents (ages =13) when other treatments have not been effective. The product incorporates nemolizumab, a humanized monoclonal antibody that targets the interleukin-31 (IL-31) receptor, and by inhibiting IL-31, the medication seeks to ease itching and improve the quality of life for patients experiencing these conditions.

Who Are The Top-Performing Companies In The Pruritus Therapeutics Market In Recent Years?

Major companies operating in the pruritus therapeutics market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Galderma Laboratories LP, Cipla Limited, LEO Pharma AS, Cara Therapeutics Inc., GlaxoSmithKline Plc, Novan Inc., Trevi Therapeutics Inc., AbbVie Biopharmaceuticals, Amgen Inc., Allergan plc, Horizon Therapeutics plc, Kyowa Kirin Co. Ltd., Dermira Inc., Pfizer Consumer Healthcare

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report

Which Region Currently Holds The Largest Share Of The Pruritus Therapeutics Market?

North America was the largest region in the pruritus treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pruritus therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Pruritus Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11907&type=smp

Browse Through More Reports Similar to the Global Pruritus Therapeutics Market 2026, By The Business Research Company

Pruritus Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report

Pruritus Therapeutic Market Report 2026

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutic-global-market-report

Pertussis Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/pertussis-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the pruritus therapeutics market from 2026–2035 with trusted insights from The Business Research Company

What level of CAGR-driven expansion is anticipated in the Pruritus Therapeutics Market between 2026 and 2030?

The pruritus therapeutics market has experienced significant expansion in recent years. Its size is expected to rise from $12.38 billion in 2025 to $13.08 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.6%. This growth observed historically is attributable to factors like the increasing occurrence of inflammatory skin diseases, greater utilization of corticosteroids and antihistamines, an uplift in dermatology research funding, the expansion of hospital and clinic networks, and the early embrace of topical therapies.

The pruritus therapeutics market size is anticipated to experience robust expansion over the coming years. Projections indicate it will reach $16.88 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 6.6%. This projected growth is driven by several factors, including developments in genomics and precision medicine, the emergence of novel immunosuppressant drugs, the increase in digital health and remote dermatology solutions, the expansion of otc pruritus products, and a heightened emphasis on managing chronic skin diseases. Key trends anticipated during this period encompass personalized pruritus treatment approaches, a greater focus on anti-inflammatory therapies, the development of topical formulations and delivery systems, the broadening availability of over-the-counter (otc) pruritus products, and a rising awareness of chronic skin conditions.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11907&type=smp

What Drivers Are Affecting Demand-Supply Dynamics In The Pruritus Therapeutics Market?

The growing occurrence of skin conditions is anticipated to drive the expansion of the pruritus therapeutics market in the future. These disorders encompass conditions affecting the skin, hair, nails, and mucous membranes, varying from common issues like acne and eczema to more severe ones such as skin cancer and fungal infections. The specific origin of itching frequently dictates the selection of pruritus treatments employed for various skin ailments. Treatment approaches for this condition include topical applications, emollients and moisturizers, immunosuppressant drugs, and anti-itch medications. For instance, in January 2024, the American Cancer Society, a US-based non-profit organization dedicated to eliminating cancer, reported an anticipated 108,270 cases of skin cancer, which represents a 3.2% increase from the 104,930 cases reported in 2023. Consequently, the increased frequency of dermatological conditions is propelling the expansion of the pruritus therapeutics market.

How Is The Pruritus Therapeutics Market Organized Into Various Segments?

The pruritus therapeutics market covered in this report is segmented –

1) By Product: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressants, Calcineurin Inhibitors, Other Products

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types

4) By End-User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Corticosteroids: Topical Corticosteroids, Systemic Corticosteroids

2) By Antihistamines: First-Generation Antihistamines, Second-Generation Antihistamines

3) By Local Anesthetics: Topical Local Anesthetics

4) By Counterirritants: Menthol-Based Products, Camphor-Based Products

5) By Immunosuppressants: Topical Immunosuppressants, Systemic Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus Ointment, Pimecrolimus Cream

7) By Other Products: Moisturizers And Emollients, Antipruritic Herbal Remedies, Combination Therapies

Which Trends Are Guiding The Evolution Of The Pruritus Therapeutics Market?

Leading companies in the pruritus therapeutics market are prioritizing the development of advanced biologic therapies, such as monoclonal antibody treatments, to precisely address and reduce itching linked to conditions like atopic dermatitis and prurigo nodularis. Monoclonal antibody treatment employs laboratory-manufactured molecules designed to target specific proteins in the body, which are often implicated in disease processes. Illustratively, in June 2024, Maruho Co., Ltd., a Japan-based pharmaceutical firm, introduced Mitchga Subcutaneous Injection (30mg vials) in Japan. This product is for treating pruritus related to atopic dermatitis in children (ages 6-13) and prurigo nodularis in adults and adolescents (ages =13) when other treatments have not been effective. The product incorporates nemolizumab, a humanized monoclonal antibody that targets the interleukin-31 (IL-31) receptor, and by inhibiting IL-31, the medication seeks to ease itching and improve the quality of life for patients experiencing these conditions.

Who Are The Top-Performing Companies In The Pruritus Therapeutics Market In Recent Years?

Major companies operating in the pruritus therapeutics market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Bausch Health Companies Inc., Galderma Laboratories LP, Cipla Limited, LEO Pharma AS, Cara Therapeutics Inc., GlaxoSmithKline Plc, Novan Inc., Trevi Therapeutics Inc., AbbVie Biopharmaceuticals, Amgen Inc., Allergan plc, Horizon Therapeutics plc, Kyowa Kirin Co. Ltd., Dermira Inc., Pfizer Consumer Healthcare

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report

Which Region Currently Holds The Largest Share Of The Pruritus Therapeutics Market?

North America was the largest region in the pruritus treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pruritus therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Pruritus Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11907&type=smp

Browse Through More Reports Similar to the Global Pruritus Therapeutics Market 2026, By The Business Research Company

Pruritus Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report

Pruritus Therapeutic Market Report 2026

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutic-global-market-report

Pertussis Vaccine Market Report 2026

https://www.thebusinessresearchcompany.com/report/pertussis-vaccine-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the pruritus therapeutics market from 2025–2034 with trusted insights from The Business Research Company

What Are The Future Growth Projections For The Pruritus Therapeutics Market Size?

The pruritus therapeutics market size has seen steady expansion in recent years. It is anticipated to increase from $11.89 billion in 2024 to $12.38 billion in 2025, achieving a compound annual growth rate (CAGR) of 4.1%. The expansion observed in the past can be attributed to an increase in the occurrence of pruritus, various contributing causes and conditions, a growing elderly population, and a focus on enhancing the quality of life for patients.

The pruritus therapeutics market is projected to experience substantial expansion in the coming years. This market is anticipated to reach “$15.7 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 6.1%. This projected growth during the forecast period is fueled by several factors, including an expanding understanding of pruritus pathophysiology, the emergence of innovative drug formulations and delivery methods, a concentrated focus on personalized medicine, a surge in dermatological research and development, rising awareness and diagnosis rates, and an increasing appeal for botanical and herbal remedies. Key trends expected within this period involve the creation of itch-specific receptor agonists and antagonists, a market-wide focus on individualized therapeutic strategies, the incorporation of technology into itch monitoring and management, and collaborative efforts for cross-disciplinary research.

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11907&type=smp

What Core Market Drivers Are Expanding The Pruritus Therapeutics Industry?

An anticipated increase in dermatological conditions is projected to boost the expansion of the pruritus therapeutics market. These disorders encompass conditions affecting the skin, hair, nails, and mucous membranes, spanning from common issues like acne and eczema to more severe ones such as skin cancer and fungal infections. The specific etiology of itching frequently dictates the selection of pruritus treatments for various skin-related ailments. Such treatments include local applications, softening agents and hydrating creams, immune-suppressing drugs, and antipruritic medicines. As an illustration, in January 2024, the American Cancer Society, a US-based non-profit dedicated to eradicating cancer, projected 108,270 reported skin cancer cases, signifying a 3.2% increase from the 104,930 cases documented in 2023. Consequently, the growing occurrence of dermatological conditions is fueling the expansion of the pruritus therapeutics market.

What Segment Insights Are Highlighted In The Pruritus Therapeutics Market Report?

The pruritus therapeutics market covered in this report is segmented –

1) By Product: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressants, Calcineurin Inhibitors, Other Products

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types

4) By End-User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Corticosteroids: Topical Corticosteroids, Systemic Corticosteroids

2) By Antihistamines: First-Generation Antihistamines, Second-Generation Antihistamines

3) By Local Anesthetics: Topical Local Anesthetics

4) By Counterirritants: Menthol-Based Products, Camphor-Based Products

5) By Immunosuppressants: Topical Immunosuppressants, Systemic Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus Ointment, Pimecrolimus Cream

7) By Other Products: Moisturizers And Emollients, Antipruritic Herbal Remedies, Combination Therapies

Which Notable Trends Are Transforming The Pruritus Therapeutics Market Outlook?

Major companies operating in the pruritus therapeutics market are concentrating on developing targeted therapies for rare diseases and specific patient populations, utilizing methods such as non-systemic ileal bile acid transport inhibitors to deliver personalized medicine that addresses unfulfilled medical needs. A non-systemic ileal bile acid transport inhibitor functions by targeting bile acid absorption within the intestine without substantially affecting the body’s overall systemic circulation, thereby mitigating potential side effects. As an illustration, in June 2023, Ipsen, a France-based pharma company, secured approval from the Food and Drug Administration (FDA), a US-based federal agency of the Department of Health and Human Services, for Bylvay (odevixibat) to treat cholestatic pruritus in individuals aged 12 months and older suffering from Alagille syndrome (ALGS). Bylvay, administered once daily, is a non-systemic ileal bile acid transport inhibitor (IBATi) with minimal systemic exposure, representing the initial drug sanctioned for cholestatic pruritus caused by progressive familial intrahepatic cholestasis (PFIC) in the U.S. This medication had previously obtained approval for PFIC treatment in Europe and is currently accessible by prescription for eligible ALGS patients.

Which Firms Are Driving Innovation Within The Pruritus Therapeutics Market?

Major companies operating in the pruritus therapeutics market include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc. , Bausch Health Companies Inc., Galderma Laboratories LP, Cipla Limited, LEO Pharma AS, Cara Therapeutics Inc., GlaxoSmithKline Plc, Novan Inc., Escient Pharmaceuticals Inc., Nerre Therapeutic Ltd., EPI Health LLC, Trevi Therapeutics Inc., Evelo Biosciences, Toray Medical Co. Ltd.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report

What Regional Trends Are Shaping Growth In The Pruritus Therapeutics Market?

North America was the largest region in the pruritus treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=11907&type=smp

Browse Through More Reports Similar to the Global Pruritus Therapeutics Market 2025, By The Business Research Company

Blood Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Cancer Biologics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Rituximab Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

How Much Was The Pruritus Therapeutics Market Worth In 2025, And What Is Its Anticipated Value By 2029?

The pruritus therapeutics market has demonstrated consistent expansion in recent years. Its valuation is set to increase from $11.89 billion in 2024 to $12.38 billion in 2025, progressing at a compound annual growth rate (CAGR) of 4.1%. This historical development can be ascribed to a rise in the occurrence of pruritus, the wide range of its causes and associated conditions, a growing elderly population, and an emphasis on enhancing patient quality of life.

The pruritus therapeutics market size is poised for substantial expansion over the next few years. It is forecast to achieve a valuation of “$15.7 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 6.1%. This projected growth throughout the forecast period stems from factors such as an deepening comprehension of pruritus pathophysiology, the emergence of innovative drug formulations and delivery methods, an increased emphasis on personalized medicine, a surge in dermatological research and development activities, rising awareness and improved diagnosis rates, and a growing inclination towards botanical and herbal remedies. Significant trends anticipated during this period include the advancement of itch-specific receptor agonists and antagonists, a market-wide focus on personalized therapeutic approaches, the integration of technology for monitoring and managing itch, and increased collaborations for cross-disciplinary research.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11907&type=smp

Which Industry Drivers Are Expected To Accelerate The Pruritus Therapeutics Market From 2025 To 2029?

An anticipated increase in the incidence of dermatological disorders is expected to drive the growth of the pruritus therapeutics market going forward. Dermatological disorders encompass conditions of the skin, hair, nails, and mucous membranes, varying from common issues like acne and eczema to more severe cases such as skin cancer and fungal infections. The specific underlying cause of itching frequently dictates the choice of pruritus treatments for these dermatological illnesses. This condition often utilizes topical treatments, emollients and moisturizers, immunosuppressant medications, and itching medications. For instance, in January 2024, the American Cancer Society, a US-based non-profit organization dedicated to eliminating cancer, reported that there would be 108,270 cases of skin cancer, reflecting a 3.2% increase from the 104,930 cases reported in 2023. Consequently, the rising occurrence of dermatological disorders is fueling the growth of the pruritus therapeutics market.

What Are The Key Segments In The Pruritus Therapeutics Market?

The pruritus therapeutics market covered in this report is segmented –

1) By Product: Corticosteroids, Antihistamines, Local Anesthetics, Counterirritants, Immunosuppressants, Calcineurin Inhibitors, Other Products

2) By Route Of Administration: Oral, Parenteral, Topical

3) By Disease Type: Atopic Dermatitis, Allergic Contact Dermatitis, Urticaria, Cutaneous T-Cell, Other Disease Types

4) By End-User: Hospitals, Clinics, Other End Users

Subsegments:

1) By Corticosteroids: Topical Corticosteroids, Systemic Corticosteroids

2) By Antihistamines: First-Generation Antihistamines, Second-Generation Antihistamines

3) By Local Anesthetics: Topical Local Anesthetics

4) By Counterirritants: Menthol-Based Products, Camphor-Based Products

5) By Immunosuppressants: Topical Immunosuppressants, Systemic Immunosuppressants

6) By Calcineurin Inhibitors: Tacrolimus Ointment, Pimecrolimus Cream

7) By Other Products: Moisturizers And Emollients, Antipruritic Herbal Remedies, Combination Therapies

How Are Trends Influencing The Pruritus Therapeutics Market?

Leading companies in the pruritus therapeutics market are focusing on developing specialized treatments for rare diseases and particular patient groups, such as those involving non-systemic ileal bile acid transport inhibitors, to deliver personalized medicine addressing unmet medical needs. A non-systemic ileal bile acid transport inhibitor is a type of drug that specifically targets bile acid absorption in the intestine, minimizing its impact on systemic circulation and thereby reducing potential side effects. As an illustration, in June 2023, Ipsen, a France-based pharmaceutical company, secured approval from the Food and Drug Administration (FDA), a US-based federal agency of the Department of Health and Human Services, for Bylvay (odevixibat). This approval is for the treatment of cholestatic pruritus in patients aged 12 months and older who have Alagille syndrome (ALGS). Bylvay, a once-daily, non-systemic ileal bile acid transport inhibitor (IBATi), demonstrates minimal systemic exposure and marks the first drug approved in the U.S. for cholestatic pruritus resulting from progressive familial intrahepatic cholestasis (PFIC). Previously approved for PFIC treatment in Europe, it is now available by prescription for eligible ALGS patients.

Who Are The Prominent Global Companies Shaping The Pruritus Therapeutics Market?

Major companies operating in the pruritus therapeutics market include Pfizer Inc., Johnson & Johnson, AbbVie Inc., Sanofi S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Regeneron Pharmaceuticals Inc., Astellas Pharma Inc. , Bausch Health Companies Inc., Galderma Laboratories LP, Cipla Limited, LEO Pharma AS, Cara Therapeutics Inc., GlaxoSmithKline Plc, Novan Inc., Escient Pharmaceuticals Inc., Nerre Therapeutic Ltd., EPI Health LLC, Trevi Therapeutics Inc., Evelo Biosciences, Toray Medical Co. Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/pruritus-therapeutics-global-market-report

Which Geographies Are Emerging As Strong Markets For The Pruritus Therapeutics Industry?

North America was the largest region in the pruritus treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pruritus therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Pruritus Therapeutics Market Report:

https://www.thebusinessresearchcompany.com/customise?id=11907&type=smp

Browse Through More Reports Similar to the Global Pruritus Therapeutics Market 2025, By The Business Research Company

Blood Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/blood-cancer-drugs-global-market-report

Cancer Biologics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/cancer-biologics-global-market-report

Rituximab Biosimilar Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/rituximab-biosimilar-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model